AKT1 and renal carcinoma: Moreover, the angiogenesis studies demonstrated that the suppression of S100A16 may reduce the expression levels of VEGF, VEGFR2, and p-Akt in renal cancer cells, consequently diminishing their angiogenesis capacities.